<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01289054</url>
  </required_header>
  <id_info>
    <org_study_id>CSTI571A2403</org_study_id>
    <nct_id>NCT01289054</nct_id>
  </id_info>
  <brief_title>A Global Imatinib and Nilotinib Pregnancy Exposure Registry</brief_title>
  <official_title>A Global Imatinib and Nilotinib Pregnancy Exposure Registry A Post-Authorisation Safety Study (PASS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This is a voluntary, international, primarily prospective, observational, exposure-registry
      and follow-up study of women receiving Imatinib and Nilotinib during pregnancy or within six
      months prior to pregnancy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Monitor pregnancies exposed to Imatinib or Nilotinib to estimate prevalence of birth defects</measure>
    <time_frame>During pregnancy or within 6 months prior to conception</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess impact on maternal CML disease when treatment is interrupted</measure>
    <time_frame>During pregnancy or within 6 months prior to conception</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess post 12 month post-delivery data on maternal and infant status</measure>
    <time_frame>12 months after birth</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">4</enrollment>
  <condition>All Indications for Glivec/Gleevec and Tasigna</condition>
  <arm_group>
    <arm_group_label>Cohort 1 - Pregnancy/Fetal Exposure</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 - Interrupted TKI</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tasigna</intervention_name>
    <arm_group_label>Cohort 1 - Pregnancy/Fetal Exposure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gleevec</intervention_name>
    <arm_group_label>Cohort 1 - Pregnancy/Fetal Exposure</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women exposed to any dose of Gleevec/Glivec or Tasigna during pregnancy or within 6 months
        prior to conception
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide sufficient evidence to confirm that exposure occurred during pregnancy or
             within 6 months prior to exposure.

          -  Be at least 18 years of age

          -  Reside in a country supported by the Registry

        Exclusion Criteria:

          -  Cases that do not meet the eligibility criteria are deemed ineligible, including
             paternal exposures

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>INC Research, LLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2011</study_first_submitted>
  <study_first_submitted_qc>February 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2011</study_first_posted>
  <last_update_submitted>April 14, 2015</last_update_submitted>
  <last_update_submitted_qc>April 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Female</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Hematologic Pregnancy</keyword>
  <keyword>Complications</keyword>
  <keyword>Registry</keyword>
  <keyword>Pregnant Registry</keyword>
  <keyword>CML</keyword>
  <keyword>GIST</keyword>
  <keyword>Gleevec</keyword>
  <keyword>Tasigna</keyword>
  <keyword>Glivec</keyword>
  <keyword>Pregnancy Exposure</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

